Abbott Receives Three CES 2023 Innovation Awards for Advancements in Health Technology

• The Consumer Technology Association (CTA) awards Abbott multiple CES 2023 Innovation Awards for industry-leading health technologies
• Abbott’s Aveir™ single-chamber (VR) leadless pacemaker, Proclaim™ Plus SCS system, Alinity^® m Monkeypox PCR test honored
• Other recent Abbott innovation honors include Abbott’s FreeStyle Libre^® technology named the best medical technology in the last 50 years by the Galien Foundation

ABBOTT PARK — Abbott (NYSE: ABT) has been recognized by the Consumer Technology Association (CTA) with three CES 2023 Innovation Awards for its life-changing technologies that are advancing the health tech industry and improving the lives of people worldwide. The CTA is the organization behind the Consumer Electronics Show (CES), the most influential technology event in the world.

Ahead of the CES 2023 event, three of Abbott’s industry-leading tech advancements won CES 2023 Innovation Awards, all within the Digital Health award category:

• Aveir VR Leadless Pacemaker – The world’s only leadless pacemaker with a unique mapping capability to assess correct positioning prior to placement and designed to be completely retrievable. The system was developed by Abbott to treat patients with slow heart rhythms and eliminates wires used to deliver therapy in traditional pacemakers.
• Proclaim Plus SCS System – Abbott’s latest advancement in neurostimulation therapy to treat chronic pain using low doses of targeted BurstDR™ stimulation that can be adjusted as a person’s therapeutic needs evolve across up to six areas of the body, which is more pain sites in the body than ever before.
• Alinity m Monkeypox PCR test¹ – A first of its kind, Abbott received FDA Emergency Use Authorization of its PCR test for detecting the monkeypox virus.  

The CES Innovation Awards program is an annual competition honoring outstanding design and engineering in consumer technology products. The program recognizes the year’s most innovative products in a multitude of consumer technology product categories and distinguishes the highest-rated in each.

Last year, Abbott became the first-ever healthcare company to keynote CES, and the company has received nine CES Innovation Awards in the past two years.

Other Abbott products previously honored with CES Innovation Awards include FreeStyle Libre 3², the world’s smallest, thinnest³ and most accurate⁴ 14-day glucose sensor and a CES 2022 Best of Innovation Award winner; BinaxNOW™⁵, the #1 COVID-19 self test in the U.S.; and the Ultreon^TM 1.0 intravascular imaging and coronary physiology software platform, which helps guide and optimize stenting decisions, combining optical coherence tomography with artificial intelligence.

In addition to the CES 2023 awards, Abbott also was recently recognized with other top honors for its healthcare technology including its revolutionary FreeStyle Libre technology being named the best medical technology in the last 50 years by the Galien Foundation. The FreeStyle Libre portfolio has transformed the lives of approximately 4.5 million people⁶ living with diabetes globally.